Aerpio Pharmaceuticals, Inc. (ARPO) News
Filter ARPO News Items
ARPO News Results
|Loading, please wait...|
ARPO News Highlights
- ARPO's 30 day story count now stands at 5.
- Over the past 15 days, the trend for ARPO's stories per day has been choppy and unclear. It has oscillated between 2 and 3.
- The most mentioned tickers in articles about ARPO are ALTA, MTOR and ROCK.
Latest ARPO News From Around the Web
Below are the latest news stories about Aerpio Pharmaceuticals Inc that investors may wish to consider to help them evaluate ARPO as an investment opportunity.
LOS ANGELES, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Aadi) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the closing of its previously announced merger with Aerpio Pharmaceuticals, Inc. (previously traded on the Nasdaq Capital Market under ARPO).
Earnings results for Aerpio Pharmaceuticals , Analyst Opinion on Aerpio Pharmaceuticals , Earnings and Valuation of (NASDAQ:ARPO), Stock market Insights & financial analysis, Best stock to invest, Investment Idea, The post Earnings Report: Heres what to expect from Aerpio Pharmaceuticals (NASDAQ:ARPO) appeared first on .
CINCINNATI, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (Aerpio) (Nasdaq: ARPO), a biopharmaceutical company, today reported financial results for the three and six months ended June 30, 2021 and provided a business update.
Welcome back, trader!
INVESTIGATION ALERT: Halper Sadeh LLP Investigates ONEM, SYKE, NETE, CHMA, SOLY, ARPO; Shareholders are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Aerpio Pharmaceuticals (ARPO) is a biopharmaceutical company focused on developing compounds that activate Tie2. Tie2 is considered a key regulator of vascular stability, and ARPO “believes that activation of Tie2 may have therapeutic potential” for different indications. In Q1, ARPO did not earn any revenues, but net loss widened to $4.4 million from $3.9 million in the same quarter a year ago. Aerpio’s operating expenses increased 36.7% year-over-year to $5.6 million in Q1. The company had cash and cash equivalents of $39 million as of March 31. Merger with Aadi Bioscience In May, Aerpio announced the merger with Aadi Bioscience.
Good morning, investor!
Aerpio Pharmaceuticals (ARPO) stock is flying high on Thursday after an analyst upgrade gave the company's shares a boost today.
Digital Brands (DBGI) stock is rocketing higher on Thursday after revealing estimated financial data for its upcoming quarter.
SHAREHOLDER ALERT: WeissLaw LLP Reminds SPRT, FI, NETE, and ARPO Shareholders About Its Ongoing Investigations
If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: